LKT Labs

Biochemicals for Life Science Research

MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.00 In stock
5 mg $219.00 In stock
10 mg $337.00 In stock
Bulk Quote

Quicklinks

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2
Purity

≥98%
Formula

C27H20ClFN4O4
Formula Wt.

518.92
IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
Synonym

Alisertib
Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble
Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF
Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • E4668

    ELR-510444

    Microtubule polymerization inhibitor.

    ≥98%
  • B5871

    Bortezomib

    Proteasome inhibitor.

    ≥98%
  • G8103

    Guanylin, human

    Endogenous peptide hormone; guanyl cyclase C ag...

    ≥95%
  • B165122

    Bedaquiline

    Bactericidal

    ≥99%
  • D0033

    Daidzin

    Isoflavone, phytoestrogen, found in soy.

    ≥98%
  • K0652

    Kb NB 142-70

    PKD inhibitor.

    ≥98%
  • D0244

    Dalcetrapib

    Cholesterol ester transfer protein inhibitor.

    ≥98%
  • M184770

    4-O-Methylhonokiol

    Found in Magnolia officinalis.

    ≥98%
  • T3100

    Thyrotropin-releasing Hormone

    Endogenous tripeptide, involved in HPA signalin...

    ≥95%
  • R1626

    Regorafenib Monohydrate

    VEGFR1/2/3, TIE2, PDGFRβ, FGFR1, c-Kit, RET, B...

    ≥99%
  • C0243

    Calcitonin Gene Related Peptide (8-37), human

    Calcitonin-family peptide frgament, involved in...

    ≥95%
  • P6870

    Propofol

    GABA-A agonist, NMDA antagonist, voltage-gated ...

    ≥98%
  • C0247

    Calcineurin Autoinhibitory Peptide

    Peptide; calcineurin inhibitor.

    ≥95%
  • B4514

    Bleomycin A5 Hydrochloride Cu

    Induces apoptosis, DNA cleavage and strand brea...

    ≥85%
  • P7058

    Protocatechuic Aldehyde

    Polyphenol found in various plants and foods.

    ≥98%
  • G0145

    Gallic Acid

    Phenol found in various plant sources, used to ...

    ≥98%
  • C3263

    Ciprofloxacin Hydrochloride Monohydrate

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • N3346

    Nilotinib

    Phenylamino pyridine; Abl, c-Kit, PDGFR, PP2A i...

    ≥99%
  • O7332

    OSI-027

    mTOR inhibitor.

    ≥99%
  • C1621

    CEF4

    Peptide, vSrc-induced cytokine.

    ≥95%